Treatment of Benign Prostatic Enlargement with Alpha-blockers: an Updated Review

REFERENCES

• Caine M, Raz S. Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 47: 193–202.
   Google Scholar
• Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50: 551–6.
   Google Scholar
• Chapple CR, Aubry ML, James S, Greengrass PM, Bumstock G, Turner-Warwick RT, et al. Characteriza-tion of human prostatic adrenoceptors using pharmacol-ogy receptor binding and localisation. Br J Urol 1989; 63: 487–96.
   Google Scholar
• Hedlund H, Andersson K-E, Larsson B. oc-adrenoceptors and muscarinic receptors in the isolated human prostate. J Urol 1985; 134: 1291–8.
   Google Scholar
• Hieble JP, Caine M, Zalaznik E. In vitro characteriza-tion of oc-adrenoceptors in human prostate. Eur J Pharmacol 1985; 107: 111–17.
   Google Scholar
• Lepor H, Shapiro E. Characterization of the oci-adrenergic receptor in human benign prostatic hyper-plasia. J Urol 1984; 132: 1226–9.
   PubMed Web of Science ®Google Scholar
• Hedlund H, Andersson K-E, Ek A. Preliminary effects of prazosin on the human bladder and urethra in vitro and in vivo. In: Proceedings of the Ninth Annual Meeting of the International Continence Society, Rome, Italy, 1979: 90.
   Google Scholar
• Chapple CR, Christmas TJ, Milroy EJG. A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction. Urol Int 1990; 45 Suppl 1: 47–55.
   Google Scholar
• Kirby RS, Coppinger SWC, Corcoran MO, Chapple CR, Flanningan M, Milroy EJG. Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. Br J Urol 1987; 60: 136–42.
   PubMedGoogle Scholar
• Hedlund H, Andersson K-E, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol 1983; 130: 275–8.
   Google Scholar
• Bartsch G, Muller HR, Oberholzer M, Rohr HP. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979; 122: 487–91.
   PubMed Web of Science ®Google Scholar
• Andersson K-E, Lepor H, Wyllie MG. Prostatic adrenoceptors and uroselectivity. The Prostate 1997; 30: 202–15.
   Google Scholar
• Abrams PH. New words for old: lower urinary tract symptoms for "prostatism". Br Med J 1994; 308: 929–30.
   PubMed Web of Science ®Google Scholar
• Lepor H, Tang R, Meretyk S, Shapiro E. ocradreno-ceptor subtypes in the human prostate. J Urol 1993; 149: 640–2.
   PubMed Web of Science ®Google Scholar
• Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, et al. The c1-adrenergic receptor that mediates smooth muscle contraction in human prostate has pharmacological properties of the cloned human alpha lc subtype. Mol Pharmacol 1994; 45: 703–8.
   PubMed Web of Science ®Google Scholar
• Price DT, Schwinn DA, Lomasney LF, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification and localization of mRNA for three distinct c1-adrenergic receptor subtypes in human prostate. J Urol 1993; 150: 546–51.
   PubMed Web of Science ®Google Scholar
• Kenny BA, Miller AM, Williamson IJR, Oconnell J, Chalmers DH, Naylor AM. Evaluation of the pharma-cological selectivity profile of c1-adrenoceptor antago-nists at prostatic c1-adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 1996; 118: 871–8.
   PubMed Web of Science ®Google Scholar
• Kenny BA, Naylor AM, Carter AJ, Read AM, Green-grass PM, Wyllie MG. Effect of ocradrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetised dog. Urology 1994; 44: 52–7.
   Google Scholar
• Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110–15.
   PubMed Web of Science ®Google Scholar
• En i LM, Tveter KJ. cc-blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 154: 923–34.
   PubMed Web of Science ®Google Scholar
• Narayan P. Tewari A. Overview of cc-blocker therapy for benign prostatic hyperplasia. Urology 1998; 51 Suppl 4A: 38–45.
   Google Scholar
• Buzelin JM, Herbert M, Blondin Pand the PRAZALF group. cc-blocking treatment with alfuzo sin in sympto-matic benign prostatic hyperplasia: comparative study with prazosin. Br J Urol 1993; 72: 922–7.
   Google Scholar
• Lepor H, Laddu A. Terazo sin in the treatment of benign prostatic hyperplasia: the United States experience. Br J Urol 1992; 70, Suppl 1: 2–9.
   PubMedGoogle Scholar
• Roerbom CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DF, et al. The hytrin community assessment trial study: a one-year study of terazosin versus placebo in the treatment of men with sympto-matic benign prostatic hyperplasia. Urology 1996; 47: 159–68.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Wundaele JJ, Nordling J, Boeminghaus F, Ypma AFGVM, Abrams P. Tamsulosin, the first prostate-selective ociA-adrenoceptor antagonist: a meta-analysis of two randomized, placebo-controlled multi-centre studies in patients with benign prostatic obstruc-tion (symptomatic BPH). Eur Urol 1996; 29: 155–67.
   PubMed Web of Science ®Google Scholar
• Roerbom CG, Siegel RE. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled stu-dies. Urology 1996; 48: 406–15.
   PubMed Web of Science ®Google Scholar
• Jardin A, Bensadoun H, Delauche Cavallier MC, Attali P. Alfuzosin for treatment of benign prostatic hyper-trophy. The BPH-ALF Group. Lancet 1991; 337: 1457–61.
   PubMed Web of Science ®Google Scholar
• Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC and the ALGEBI study group. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1997; 31: 190–8.
   Google Scholar
• Kaplan SA, Meade-Dalisera P. Quinones S, Soldo KA. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urology 1995; 46: 512–17.
   Google Scholar
• Kirby RS. Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normo-tensive and hypertensive men. Urology 1995; 46: 182–6.
   PubMed Web of Science ®Google Scholar
• Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533–9.
   PubMed Web of Science ®Google Scholar
• Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato HYM617 Clinical Study Group. Use of an cc-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 1990; 144: 908–12.
   Google Scholar
• Yamada S, Tanaka C, Ohkura T, Mori R, Kimura R, Inagaki O, et al. High-affinity specific (3H)tamsulosin binding c1-adrenoceptors in human prostates with benign prostatic hypertrophy. Urol Res 1994; 22: 273–8.
   PubMedGoogle Scholar
• Michel MC, Buscher R, Kerker J, Kraneis H, Erdbrug-ger W, Brodde O-E. Alpha-1 adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethyl-clonidine-restistant rat renal ocradrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 385–95.
   Google Scholar
• Chapple CR. Pharmacotherapy for benign prostatic hyperplasia - the potential for aradrenoceptor sub-type-specific blockade. Br J Urol 1998; 81 Suppl 1: 34–47.
   PubMedGoogle Scholar
• Lowe FC. Co-administration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997; 19: 730–42.
   PubMed Web of Science ®Google Scholar
• Lepor H, and the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin, a prostate selective al-antagonist. J Urol 1996; 155: 585A.
   Google Scholar
• Chapple CR, Stott M, Abrams PH, Cristmas TJ, Milroy EJG. A 12 week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br J Urol 1992; 70: 285–94.
   Google Scholar
• Witjes WPJ, Rosier PFWM, Canis CTM, Debruyne FMJ, de la Rosette JJM. Urodynamic and clinical effects of terazo sin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis. Urology 1997; 49: 197–206.
   Google Scholar
• Kawabe K. Current status of research on prostate-selective al-antagonists. Br J Urol 1998; Suppl 1: 48–50.
   Google Scholar